Feed CYTK
CY

Cytokinetics

CYTK · NASDAQ

$67.56 -1.40% (-$0.96)
1M -12.36%
Market Cap $8.41B
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
1/9
Valuation
0 /100
Expensive
P/S 118.47x
EV/FFO N/A
P/E N/A
Growth
8 /100
Declining
Rev. growth 2.36%
Book val. growth N/A
EPS growth N/A
Profitability
20 /100
Weak
Op. margin 992.98%
Gross margin 84.97%
FCF margin 818.37%
Quality
1 /100
Poor
Asset turnover 0.04x
ROIC 39.33%
ROA 46.45%
Debt
43 /100
Moderate
Int. coverage -6.68x
Current ratio 6.66x
Debt/Assets N/A
Stability
40 /100
Moderate
EPS volatility 16.52%
Beta 0.36x
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o CYTK
Online

O podjetju

Cytokinetics, Incorporated is an American biotechnology company specializing in the development of therapeutic approaches aimed at improving muscle function in patients with heart and muscle diseases. The company develops innovative drug candidates targeting the regulation of muscle proteins, which can help treat conditions such as heart failure, amyotrophic lateral sclerosis (ALS), and other muscle disorders. Cytokinetics focuses on providing new treatment options for patients for whom current therapies are insufficiently effective.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Robert I. Blum

Employees

673

Headquarters

South San Francisco

Prihajajoči dogodki

04 NOV.

Earnings

Upcoming earnings report

43d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.